Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 5Leukemia 5Ovarian Neoplasms 4Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Precancerous Conditions 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, Large-Cell, Anaplastic 3Immunoblastic Lymphadenopathy 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Central Nervous System Neoplasms 3Burkitt Lymphoma 3Adenocarcinoma Of Esophagus 3Tongue Neoplasms 2Testicular Germ Cell Tumor 2Stomach Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasm Metastasis 2Myeloproliferative Disorders 2

Interventions

Temozolomide 1Microarray Analysis 1DNA Methylation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenoma, Chromophobe × Microarray Analysis × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡